Analysis of pathogens and drug resistance of lower respiratory tract infection in children with severe acute respiratory syndrome
10.3969/j.issn.1005-1678.2017.05.139
- VernacularTitle:急性重症患儿下呼吸道感染病原菌及耐药性分析
- Author:
Yan XU
- Keywords:
acute severe lower respiratory tract infection;
pathogen;
drug resistance
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(5):411-413
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the distribution of pathogens in acute severe lower respiratory tract infection and drug resistance.MethodsFrom October 2014 to December 2016, selected 441 children patients with acute severe lower respiratory tract infectionin tianjinfifth centralhospital were drawn lower respiratory tract secretions from the oral endotracheal intubation of the disposable suction tube or container, bacterial culture and identification, to determine the type of bacteria, and drug susceptibility test.ResultsA total of 642pathogens were co-cultured in 441 children, of which 391 were Gram-negative bacteria, accounting for 60.90% (391/642), including Pseudomonas aeruginosa (17.45%), Acinetobacterbaumannii (14.80 %), Klebsiellapneumoniae (13.86%);Gram-positive bacteria were 150 strains, accounting for 23.36% (150/642), mainly including Staphylococcus aureus (15.58%).Gram-negative bacteria are mostly resistant bacteria and multidrug-resistant bacteria, piperacillin and imipenem resistance is relatively low.Gram-positive bacteria on penicillin, gentamicin, erythromycin and other drug resistance are high, resistance to vancomycin are low, including Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis Resistant drug resistance were 0.00%.ConclusionThe pathogens of lower respiratory tract infection in children with acute severe disease mainly include Pseudomonas aeruginosa, Acinetobacterbaumannii and Klebsiellapneumoniae and other Gram-negative bacteria, the clinical application should be based on the results of pathogen species and susceptibility test to choose reasonable antimicrobial drugs for children patients.
